Basket Trials (as of August 2, 2021)

ENGOT-GYN5/NOGGO/IMPROVE

Leading group: NOGGO

Clinical Trial Study:  Expression XI - Improve

Planned number of patients: 1000

Participating groups: 

TBA

Planned start in Q3 2021

 

ENGOT-GYN4/NOGGO/EXPRESSION IX

Leading group: NOGGO

Clinical Trial Study:  Expression IX - Longterm survival with gynecological cancer

Planned number of patients: 1000

Participating groups: 

TBA

 

ENGOT-GYN3/AGO/LIO

Leading group: AGO

Clinical Trial Study:  LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor

Planned number of patients: 161

Participating groups: 

BGOG, GEICO, MITO

 

ENGOT-GYN2/GINECO/BOUQUET

Leading group: GINECO

Clinical Trial Study:  A multicenter, multi-arm, open-label, genomics-driven phase II study evaluating the clinical benefit of molecularly targeted therapies alone or in combination in patients with progressive locally-advanced or metastatic rare gynecologic tumors after one line of systemic therapy

Planned number of patients: 20 patients per cohort

Participating groups: 

AGO, GEICO, A-AGO, BGOG, CEEGOG

 

ENGOT-GYN1/NCRI/ATARI

Leading group: NCRI

Clinical Trial Study: ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss  

Planned number of patients: 116

Participating groups: 

GINECO, Princes Margaret Consortium Canada